Establishment Labs Holdings Inc. $ESTA Stock Holdings Decreased by Findell Capital Management LLC

Findell Capital Management LLC reduced its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 12.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,130,460 shares of the company’s stock after selling 164,960 shares during the period. Establishment Labs comprises approximately 23.7% of Findell Capital Management LLC’s holdings, making the stock its largest position. Findell Capital Management LLC’s holdings in Establishment Labs were worth $82,388,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in ESTA. Goldman Sachs Group Inc. increased its position in shares of Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares in the last quarter. Viking Global Investors LP purchased a new position in shares of Establishment Labs in the second quarter worth approximately $14,669,000. Bamco Inc. NY increased its position in shares of Establishment Labs by 30.2% in the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after acquiring an additional 274,287 shares in the last quarter. Soleus Capital Management L.P. purchased a new position in shares of Establishment Labs in the second quarter worth approximately $9,050,000. Finally, Summit Partners Public Asset Management LLC increased its position in shares of Establishment Labs by 87.1% in the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after acquiring an additional 200,255 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Stock Performance

Shares of ESTA opened at $82.39 on Thursday. The company’s 50 day moving average price is $70.25 and its 200 day moving average price is $69.48. Establishment Labs Holdings Inc. has a 52 week low of $33.35 and a 52 week high of $86.00. The company has a market capitalization of $2.42 billion, a PE ratio of -55.29 and a beta of 1.11. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. During the same quarter last year, the firm earned ($0.70) earnings per share. Establishment Labs’s revenue was up 44.7% compared to the same quarter last year. Research analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ESTA. Needham & Company LLC boosted their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Canaccord Genuity Group boosted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a research report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $87.14.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 330,000 shares of company stock valued at $22,854,538 in the last three months. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.